ClinicalTrials.Veeva

Menu

Prebiotics in Rectal Cancer

O

Ochsner Health System

Status

Enrolling

Conditions

Rectal Cancer

Treatments

Dietary Supplement: Soluble Corn Fiber
Dietary Supplement: Maltodextrin

Study type

Interventional

Funder types

Other

Identifiers

NCT05516641
2021.227

Details and patient eligibility

About

A significant racial disparity in the incidence and mortality of CRC exists in the U.S. with African Americans having CRC incidence and mortality rates that are 20% and 40% higher than the general U.S. population. It has been demonstrated that the gut microbiome impacts tumor development and progression through multiple mechanisms, including impacting the tumoral immune response. However, it is unknown if microbiome modulating treatment can have an impact on CRC outcomes.

Full description

A significant racial disparity in the incidence and mortality of CRC exists in the U.S. with African Americans having CRC incidence and mortality rates that are 20% and 40% higher than the general U.S. population. It has been demonstrated that the gut microbiome impacts tumor development and progression through multiple mechanisms, including impacting the tumoral immune response. However, it is unknown if microbiome modulating treatment can have an impact on CRC outcomes.

This is a pilot project to see if any changes are detected in stool and/or tissue samples in rectal cancer patients who receive a soluble corn fiber supplement during their neoadjuvant treatment.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Aged 18 years or older
  2. Clinical diagnosis of stage 2 or stage 3 rectal cancer
  3. Subjects who are women of child-bearing potential must not be pregnant or lactating
  4. Have signed an approved informed consent form for the study
  5. Be willing to comply with the protocol

Exclusion criteria

  1. Patients with a cancer history (excluding the rectal cancer currently being addressed)
  2. Allergic to corn or maltodextrin
  3. Has, in the Investigator's opinion, any medical condition that makes the subject a poor candidate for the study

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

20 participants in 2 patient groups, including a placebo group

Prebiotic
Experimental group
Description:
Soluble Corn Fiber
Treatment:
Dietary Supplement: Soluble Corn Fiber
Control
Placebo Comparator group
Description:
Maltodextrin
Treatment:
Dietary Supplement: Maltodextrin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems